Winslow Evans & Crocker’s Juno Therapeutics, Inc. JUNO Stock Holding History

Winslow Evans & Crocker’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-500	Closed	-$9.43K	–	1298
2016 Q4	$9.43K	Hold	500	–	–	﹤0.01%	895
2016 Q3	$15K	Hold	500	–	–	﹤0.01%	807
2016 Q2	$19.2K	Hold	500	–	–	0.01%	700
2016 Q1	$19K	Hold	500	–	–	0.01%	717
2015 Q4	$22K	Hold	500	–	–	0.01%	721
2015 Q3	$20.3K	Hold	500	–	–	0.01%	718
2015 Q2	$26.7K	Hold	500	–	–	0.01%	691
2015 Q1	$30.3K	Buy	+500	New	+$24.3K	0.01%	643

Other funds holding JUNO

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BCM

Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Winslow Evans & Crocker's JUNO Position: Q1 2017 in Review

Winslow Evans & Crocker sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2017, closing a stake of 500 shares — an estimated $9.43K sold.

Winslow Evans & Crocker first reported a position in JUNO in Q1 2015 and held it in 8 quarters. The position peaked at $30.3K in Q1 2015. 157 funds tracked by Wall St. Rank hold JUNO as of Q1 2017.

Winslow Evans & Crocker reported no remaining Juno Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
Winslow Evans & Crocker sold 500 Juno Therapeutics, Inc. shares in Q1 2017, an estimated $9.43K.
Winslow Evans & Crocker first reported a position in Juno Therapeutics, Inc. in Q1 2015 and held it in 8 quarters.
Winslow Evans & Crocker's Juno Therapeutics, Inc. position peaked at $30.3K in Q1 2015.
157 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2017.

Based on Winslow Evans & Crocker's 13F filing for Q1 2017, filed 14 Apr 2017.